News

CHMP has recommended the approval of Afinitor based on data demonstrating that (when compared with placebo) Afinitor more than doubled the time without tumor growth or death in

This is a quantum leap forward in terms of accuracy with timeframes that were previously unimaginable, says Sophie Wetherall, Varian BrachyTherapy software product manager. BrachyVision Acuros offers an

The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients. Ron Bentsur, CEO of Keryx, said: We

This follows the notification to AstraZeneca by the Netherlands Health Authority (MEB), acting as the Reference Member State for the Mutual Recognition Process (MRP), that the Seroquel XR

Under the terms of the restructured deal, BioMarin has acquired full ownership of the DMD program, including the preclinical candidate, SMT C1100. BioMarin has assumed all future preclinical

Following the positive report by CHMP, Lilly has also filed for approval of ‘pemetrexed’ in the same indication with the FDA. In the European Union and US, pemetrexed

Before joining B Riley in September 2008, McQuay employed for 10 years as managing director investment banking at A. G. Edwards & Sons, Inc., where he specialized in

The company incurred a loss of $168197 in the first quarter of 2009, compared to $74067 for the same period in 2008. Management expects that greater sales of

Emsam was previously marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers.